TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

80 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Kidney disease

    A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

    Testing whether empagliflozin is safe and helps children with chronic kidney disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +29 more US sites · Get directions →

    This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD.

    ✓ Study care freePhase 3Ages 2–17Learn more →
  • Multiple sclerosis (MS)

    Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    Testing remibrutinib in people with relapsing multiple sclerosis who switch from ocrelizumab versus

    📍 Perseverance Research Center · Scottsdale, AZ · +39 more US sites · Get directions →

    The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

    ✓ Study care freePhase 3Ages 40–70Learn more →
  • Multiple sclerosis (MS)

    Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    Testing a modified ublituximab treatment for relapsing multiple sclerosis

    📍 TG Therapeutics Investigational Trial Site · Birmingham, AL · +34 more US sites · Get directions →

    The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

    Testing safety of a twice-yearly medicine for early relapsing MS

    📍 Northwestern Memorial Hospital · Chicago, IL · Get directions →

    In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Lupus (SLE)

    Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial

    Testing whether adding two lupus medicines to standard care improves kidney results

    📍 AARA Clinical Research · Glendale, AZ · +6 more US sites · Get directions →

    This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) compared to proportion of patients achieving CRR from recent clinical trials. This protocol will additionally determine whether combination therapy using Belimumab (BEL) and Voclosporin (VCS) facilitates rapid discontinuation of MMF.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Heart / cardiovascular diseaseKidney disease

    A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

    Testing whether orforglipron changes heart outcomes in adults with heart disease and/or kidney

    📍 Instituto de Investigaciones Clínicas Bahia Blanca · Bahía Blanca, · Get directions →

    The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

    ✓ Study care freePhase 3Ages 50+Learn more →
  • Kidney disease

    CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

    Comparing how two beta-blockers work in hemodialysis patients on heart outcomes

    📍 VA Long Beach Healthcare System, Long Beach, CA · Long Beach, CA · +7 more US sites · Get directions →

    The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Kidney disease

    Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

    Testing whether empagliflozin changes kidney filter injury proteins in African American Veterans

    📍 Washington DC Veterans Affairs Medical Center (688) · Washington D.C., DC · Get directions →

    Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.

    ✓ Study care freePhase 4Ages 19–90Learn more →
  • Parkinson's disease

    A Study of Buntanetap in Participants With PD

    Testing the long-term safety of buntanetap in people with Parkinson’s

    📍 University of Alabama at Birmingham · Birmingham, AL · +26 more US sites · Get directions →

    This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Multiple sclerosis (MS)

    Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

    Testing whether combining a walking medication with physical therapy improves mobility in people

    📍 MGH Institute of Health Professions · Boston, MA · Get directions →

    The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?

    ✓ Study care freePhase 4Ages 25–75Learn more →
  • Lupus (SLE)

    Dapagliflozin in Active Lupus Nephritis

    Testing dapagliflozin for lupus-related kidney inflammation (kidney disease)

    📍 Massachusetts General Hospital · Boston, MA · +1 more US site · Get directions →

    Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Lupus (SLE)

    A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

    Testing enpatoran over 24 weeks for skin lupus symptoms, with or without whole-body disease

    📍 Inland Rheumatology Clinical Trials, Inc. · Upland, CA · +7 more US sites · Get directions →

    The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Parkinson's disease

    A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

    Testing a Parkinson’s surgery approach to see if it is safe and works

    📍 Banner Sun Health Research Institute · Sun City, AZ · +32 more US sites · Get directions →

    Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).

    ✓ Study care freePhase 3Ages 45–75Learn more →
  • Parkinson's disease

    A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

    Testing a carbidopa and levodopa extended-release capsule in people with Parkinson’s

    📍 Barrow Neurological Institute · Phoenix, AZ · +26 more US sites · Get directions →

    The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Kidney disease

    Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

    Testing kidney disease drug effects and safety in teens with early CKD

    💵 May compensate

    📍 Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes · Aguascalientes, Aguascalientes · Get directions →

    Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.

    ✓ Study care freePhase 4Ages 14–18Learn more →
  • Multiple sclerosis (MS)

    A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

    Testing a drug called orelabrutinib versus placebo in people with PPMS

    📍 Arizona Neuroscience Research, LLC · Pheonix, AZ · +12 more US sites · Get directions →

    Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.

    ✓ Study care freePhase 3Ages 18–60Learn more →
  • Kidney disease

    Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

    Testing whether two dialysate salt levels affect heart events and death

    📍 Royal Adelaide Hospital · Adelaide, · Get directions →

    This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

    Comparing stem cell transplant vs best available treatment for relapsing multiple sclerosis

    📍 Stanford Multiple Sclerosis Center · Palo Alto, CA · +21 more US sites · Get directions →

    This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.

    ✓ Study care freePhase 3Ages 18–55Learn more →
  • Lupus (SLE)

    Trial of Belimumab in Early Lupus

    Testing belimumab in people with lupus diagnosed within 2 years

    📍 Feinstein Institute · Manhasset, NY · Get directions →

    This two year study will evaluate the effects of giving belimumab (Benlysta) to patients with Early Lupus. Early lupus is a diagnosis of lupus within 2 years.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Kidney disease

    A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

    Testing etelcalcetide in children with kidney disease on dialysis

    📍 Childrens Hospital of Los Angeles · Los Angeles, CA · +9 more US sites · Get directions →

    This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.

    ✓ Study care freePhase 3Learn more →
  • Type 2 diabetesKidney disease

    Mechanism of SGLT2 Inhibition in the Kidney

    Testing how SGLT2 medicines affect kidney function in type 2 diabetes

    💵 May compensate

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Lupus (SLE)

    📍 Pinnacle Research Group Llc · Anniston, AL · +20 more US sites · Get directions →

    The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).

    ✓ Study care freePhase 3Ages 12–100Learn more →
  • Kidney disease

    Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial

    Testing medicines before surgery to reduce bleeding in kidney patients

    📍 London Health Sciences Centre · London, Ontario · Get directions →

    The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Lupus (SLE)

    PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

    Testing LUPKYNIS with other lupus medicines for kidney response in lupus nephritis

    📍 Purushotham & Akther Kotha MD, Inc. · La Mesa, CA · +14 more US sites · Get directions →

    The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).

    ✓ Study care freePhase 4Ages 18–75Learn more →
  • Kidney disease

    Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

    Testing long-term safety and effectiveness of zigakibart in adults with IgA kidney disease

    📍 Colorado Kidney Care Nephrology · Denver, CO · +6 more US sites · Get directions →

    The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.

    ✓ Study care freePhase 3Ages 18–100Learn more →
  • Multiple sclerosis (MS)

    A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

    Testing orelabrutinib versus placebo for people with non-active secondary progressive multiple

    📍 Arizona Neuroscience Research, LLC · Phoenix, AZ · +12 more US sites · Get directions →

    Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS.

    ✓ Study care freePhase 3Ages 18–60Learn more →
  • Lupus (SLE)

    Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

    Testing what happens to older people with lupus if they stop their hydroxychloroquine

    📍 University of California, Los Angeles · Los Angeles, CA · +9 more US sites · Get directions →

    Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a track record of safety with regard to infection compared to traditional immunosuppressive agents, the risk of HCQ retinal toxicity escalates with continued use.

    ✓ Study care freePhase 3Ages 60+Learn more →
  • Multiple sclerosis (MS)

    Home Based Infusions for Ocrelizumab

    Testing the safety and effectiveness of home infusions of ocrelizumab for multiple sclerosis

    📍 Amerita · Centennial, CO · Get directions →

    The goal is to assess the safety and effectiveness of home ocrelizumab infusion.

    ✓ Study care freePhase 4Ages 18–55Learn more →
  • Multiple sclerosis (MS)

    📍 Local Institution - 0114 · Loma Linda, CA · +11 more US sites · Get directions →

    The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).

    ✓ Study care freePhase 3Ages 10–17Learn more →
  • Lupus (SLE)

    A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

    Testing the safety and effects of belimumab in early lupus adults

    📍 GSK Investigational Site · Anniston, AL · +39 more US sites · Get directions →

    This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable first-line SLE therapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Parkinson's disease

    18F-DOPA II - PET Imaging Optimization

    Testing an imaging scan to study Parkinson’s disease using PET

    📍 WC Mackenzie Health Science Centre / University of Alberta Hospital · Edmonton, Alberta · Get directions →

    A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism.

    ✓ Study care freePhase 3Learn more →
  • Lupus (SLE)

    A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

    Testing whether cenerimod added to usual treatment helps adults with active lupus nephritis

    💵 May compensate

    📍 Alloy Clinical Research LLC · Kissimmee, FL · +10 more US sites · Get directions →

    The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

    Testing whether sotagliflozin can slow kidney damage in type 1 diabetes

    💵 May compensate

    📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Kidney disease

    Bone in CKD Alkali Response (BICARb Pilot Trial)

    Testing whether potassium citrate improves bone health in people with chronic kidney disease

    📍 Albert Einstein College of Medicine · The Bronx, NY · +1 more US site · Get directions →

    The goal of this clinical trial is to test whether potassium citrate improves skeletal health in adults and children with chronic kidney disease. The main questions it aims to answer are: * To evaluate effects of potassium citrate treatment on bone quality and strength.

    ✓ Study care freePhase 2Ages 5–100Learn more →
  • Parkinson's disease

    Cortical Electrophysiology of Response Inhibition in Parkinson's Disease

    Studying how deep brain stimulation in Parkinson’s affects brain control of stopping actions

    📍 Emory University Hospital · Atlanta, GA · +1 more US site · Get directions →

    Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.

    ✓ Study care freePhase 4Ages 45–75Learn more →
  • Multiple sclerosis (MS)

    A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    Testing how well and how safely remibrutinib works in secondary progressive multiple sclerosis

    📍 Alabama Neurology Associates PC · Birmingham, AL · +32 more US sites · Get directions →

    The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Kidney disease

    SAfety of Regional Citrate Anticoagulation (SARCA Study)

    Testing the safety of regional citrate blood-thinner use in adults

    📍 John L. McClellan Memorial Veterans' Hospital · Little Rock, AR · +9 more US sites · Get directions →

    This is an Open-label, Prospective, Multicenter Study to Assess the SAfety of Regional Citrate Anticoagulation Delivered by the multiFiltratePRO system in Adult Patients Requiring Continuous Renal Replacement Therapy (SARCA Study).

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

    Testing whether ozanimod is safe and works as a step-down treatment for stable multiple sclerosis

    💵 May compensate

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · +2 more US sites · Get directions →

    A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Kidney disease

    EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

    Testing a treatment for adults with chronic kidney disease to help slow progression

    📍 Apogee Clinical Research · Huntsville, AL · +39 more US sites · Get directions →

    This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Kidney disease

    Patient-driven Management of BP in CKD

    Testing whether pharmacist-guided blood pressure management helps CKD patients lower blood pressure

    📍 Iowa City VA Health Care System, Iowa City, IA · Iowa City, IA · Get directions →

    The proposed research will evaluate if patients managing their blood pressure medications under the guidance of a clinical pharmacist works better to lower blood pressure than patients monitoring their blood pressure at home and the standard care. 60 Veterans with chronic kidney disease (CKD) will be included in the study.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Lupus (SLE)

    Safety of the Herpes Zoster Subunit Vaccine in Lupus

    Testing the safety of a shingles vaccine in people with lupus

    📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →

    This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The investigators hypothesize that HZ/su administration will be non-inferior to placebo with respect to the risk of moderate or severe SLE flare(s) occurring within 24 weeks of receiving the first dose of the assigned treatment.

    ✓ Study care freePhase 4Ages 18–90Learn more →
  • Multiple sclerosis (MS)

    Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

    Testing whether switching from ocrelizumab to ublituximab helps MS symptoms that return

    📍 Johns Hopkins University · Baltimore, MD · Get directions →

    The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Lupus (SLE)

    A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

    Testing a treatment called enpatoran for skin lupus symptoms over 24 weeks

    📍 Dermatology Research Associates - 300204025 · Los Angeles, CA · +10 more US sites · Get directions →

    The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Lupus (SLE)

    An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

    Testing an IV medicine to study effects and safety in children with lupus

    📍 Research Site · Phoenix, AZ · +21 more US sites · Get directions →

    A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic Lupus Erythematosus (SLE)

    ✓ Study care freePhase 3Ages 5–17Learn more →
  • Multiple sclerosis (MS)

    Glucose Consumption in MS Using [F-18]FDG-PET

    Testing how [F-18]FDG PET shows glucose use in people with MS and controls

    📍 Brigham & Women's Hospital · Boston, MA · Get directions →

    Given the need for better diagnostic imaging techniques in multiple sclerosis (MS), the study aims to investigate the utility of \[F-18\]FDG positron emission tomography (PET) in MS. The study will be assessing glucose consumption patterns in subjects with progressive MS (PMS) and relapsing-remitting MS (RRMS), as well as healthy controls.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Multiple sclerosis (MS)

    Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis

    Testing whether silodosin helps lower urinary tract symptoms in women with multiple sclerosis

    📍 Atlantic Health · Morristown, NJ · Get directions →

    The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Parkinson's disease

    BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease

    Testing a new long-acting levodopa dose to improve “on” time in Parkinson’s

    📍 Cleveland Clinic · Cleveland, OH · Get directions →

    The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias.

    ✓ Study care freePhase 4Ages 40+Learn more →
  • Multiple sclerosis (MS)

    ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

    Testing eye-tracking measures to track disease changes in relapsing-remitting multiple sclerosis

    📍 Novartis Investigative Site · Calgary, Alberta · Get directions →

    The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.

    ✓ Study care freePhase 4Ages 18–99Learn more →
  • Kidney disease

    Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

    Testing whether a weekly diabetes medicine is safe for people on dialysis

    📍 Unity Health Toronto · Toronto, Ontario · Get directions →

    This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightKidney disease

    Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

    Studying weight-loss support for people with obesity and kidney disease who want a kidney transplant

    📍 London Health Sciences Centre · London, Ontario · Get directions →

    OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Parkinson's disease

    A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    Testing an IV drug in people with early-stage Parkinson’s disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

    ✓ Study care freePhase 3Ages 50–85Learn more →
  • Lupus (SLE)

    Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

    Tracking how anifrolumab passes into breast milk and affects infants in people with lupus

    📍 Research Site · Las Vegas, NV · Get directions →

    Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users (PRIMULA Lac) is a Post Marketing Requirements (PMR) study designed to fulfill the FDA post-marketing requirements. The study will collect data about the presence of anifrolumab in human breast milk and serum (maternal and infant) among lactating individuals who are receiving anifrolumab therapeutically via intravenous (IV) or subcutaneous (SC) administration and evaluate exposure and effects on the breastfed infant.

    ✓ Study care freePhase 4Ages 18–130WomenLearn more →
  • Lupus (SLE)

    📍 Sl0044 50058 · Avondale, AZ · +39 more US sites · Get directions →

    The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

    ✓ Study care freePhase 3Ages 16+Learn more →
  • Kidney disease

    📍 Memorial Healthcare System · Hollywood, FL · +7 more US sites · Get directions →

    Primary Objectives: To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA Secondary Objective: To determine the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) profile of ferumoxytol in pediatric subjects.

    ✓ Study care freePhase 3Ages 2–17Learn more →
  • Kidney disease

    Shingrix in Renal Transplant Recipients

    Testing how well and how safely the shingles vaccine works in people with kidney failure before and

    📍 University of Colorado Anschutz · Aurora, CO · +3 more US sites · Get directions →

    The goal of this clinical trial is to learn how well the shingles vaccine (Shingrix) works and how safe it is in adults with kidney failure who are waiting for a kidney transplant, including those who later receive a transplant. The study also aims to find out whether giving an extra (third) dose of the vaccine after transplant improves protection.

    ✓ Study care freePhase 3Ages 18–70Learn more →
  • Parkinson's disease

    Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

    Comparing treatments to see which works better for hallucinations in Parkinson’s disease

    📍 Southern Arizona VA Health Care System, Tucson, AZ · Tucson, AZ · +23 more US sites · Get directions →

    Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions).

    ✓ Study care freePhase 4Ages 40+Learn more →
  • Kidney disease

    A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

    Testing an iron-based phosphate binder to lower blood phosphate in dialysis patients

    📍 Renal Consultants Medical Group · Granada Hills, CA · +18 more US sites · Get directions →

    The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lower blood phosphate levels?

    ✓ Study care freePhase 3Ages 12+Learn more →
  • Parkinson's disease

    A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's

    Testing a wearable sensor to track swallowing and drooling problems in people with Parkinson’s

    📍 Northwestern University · Evanston, IL · Get directions →

    The purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD.

    ✓ Study care freePhase 3Ages 22+Learn more →
  • Multiple sclerosis (MS)

    Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

    Testing stopping ocrelizumab in people with relapsing multiple sclerosis

    📍 Yale School of Medicine · New Haven, CT · +12 more US sites · Get directions →

    This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6,12, 18, and 24.

    ✓ Study care freePhase 4Ages 18–55Learn more →
  • Lupus (SLE)

    Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

    Testing how well and how safe a medicine is for lupus nephritis after stopping study treatment

    📍 Novartis Investigative Site · Salvador, Estado de Bahia · Get directions →

    The purpose of this 2-year extension study is the evaluation of the efficacy and safety 1. after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response \[CRR\] or partial renal response \[PRR\]) on double-blind treatment at the end of the SIRIUS-LN core study, and 2.

    ✓ Study care freePhase 3Ages 18–100Learn more →
  • Showing the first 60 of 80. Add filters or a location to narrow down.